Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVS Will Retain $300M In Drug Rebates In 2018, PBM Says

Executive Summary

CEO Merlo downplays importance of rebates to the firm’s financials as he rebuts accusations that PBMs cause high list prices for drugs.


Related Content

CVS ‘Guaranteed Net Cost’ Program Is Alternative To High Price/High Rebate Model
Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
CVS/Aetna To Merge In Defensive Play To Reshape Healthcare Delivery


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts